相关实验视频
Updated: Jun 15, 2025

11:12
Controlling Parkinson's Disease With Adaptive Deep Brain Stimulation
Published on: July 16, 2014
22.4K
在帕金森病患者中,空间分布的长期稳定性和亚thalamicβ功率的峰值动力学
Jennifer K Behnke1,2, Robert L Peach3,4,5, Jeroen G V Habets1,2
1Movement Disorders and Neuromodulation Unit, Department of Neurology, Charité University Medicine, Berlin, Germany.
概括
在帕金森病 (PD) 中的β功率是深度大脑刺激的稳定生物标志物. 它的长期稳定性支持其在自动化编程中用于自适应性刺激.
科学领域:
- 神经科学是一个神经科学.
- 生物医学工程 生物医学工程
- 运动障碍 运动障碍
背景情况:
- 亚thalamicβ振荡是帕金森病 (PD) 症状的关键生物标志物,如布拉迪基尼西亚和刚性.
- 这些振荡对于自适应性深度大脑刺激 (aDBS) 和电极接触选择至关重要.
- 了解β振荡的长期稳定性对于aDBS的有效临床应用至关重要.
研究的目的:
- 为了研究帕金森病中β峰值参数的长期动态.
- 为了分析贝塔电力分布沿深度大脑刺激电极的纵向稳定性.
主要方法:
- 在手术后0至44个月的33名PD患者中记录了局部现场潜力.
- 双极和单极β功率 (13-35 Hz) 在治疗停止条件下被分析.
- 评估了β功率和峰值频率的纵向稳定性.
主要成果:
- 贝塔峰值功率在手术后的前3个月增加.
- 虽然高贝塔峰值检测是一致的,但峰值频率显示出大量的变化.
- 沿着电极的最大贝塔功率分布表明了随着时间的推移显著的稳定性和稳定性.
- 活跃刺激接触者始终表现出比不活跃接触者更高的正常化β功率.
结论:
- 贝塔功率是一种稳定的慢性生物标志物,适合在帕金森病中进行贝塔导向编程.
- 高贝塔峰值可能会随着时间的推移为适应性刺激提供更高的可靠性.
- 微损伤效应影响神经元振荡,影响β活动稳定性,需要在自动编程中考虑.
相关概念视频
Neural Regulation
39.2K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.2K
Parkinson's Disease: Treatment
239
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
239
Parkinson's Disease: Overview
499
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
499

